Sugi Predict

Sugi Predict / Compounds / SCHEMBL4332017

SCHEMBL4332017

SCHEMBL4332017

CC(C)(C)OC(=O)N1CC1Oc1ccc(C#N)cc1

nearest known ligand 0.58

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 3/20 0.58
▸ AR P10275 1/20 0.51
▸ HRH3 Q9Y5N1 5/20 0.42
▸ PDK2 Q15119 2/20 0.40
▸ PDK1 Q15118 1/20 0.40
▸ PDK3 Q15120 1/20 0.40
▸ PDK4 Q16654 1/20 0.40
▸ GRIN1 Q05586 1/20 0.38
▸ GRIN2B Q13224 1/20 0.38
▸ NR1H2 P55055 1/20 0.38
▸ NR1H3 Q13133 1/20 0.38
▸ ALK Q9UM73 1/20 0.37
▸ EGLN2 Q96KS0 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2964269 0.82 GPR119 (0.52) GPR119ARHRH3EGLN2ALDH1A1
SCHEMBL21825090 0.82 GPR119 (0.71) GPR119ARHRH3ALK
SCHEMBL30079785 0.79 GPR119 (0.49) GPR119ARHRH3PDK2PDK1
SCHEMBL24117836 0.78 GPR119 (0.79) GPR119HRH3ALK
SCHEMBL5091205 0.78 GPR119 (0.79) GPR119HRH3ALK
SCHEMBL31632594 0.78 GPR119 (0.79) GPR119HRH3ALK
SCHEMBL225375 0.77 GPR119 (0.91) GPR119HRH3ALK
SCHEMBL30079463 0.77 GPR119 (0.45) GPR119AREGLN2ALDH1A1
SCHEMBL20989475 0.75 GPR119 (0.62) GPR119ARHRH3
SCHEMBL12094721 0.75 GPR119 (0.62) GPR119ARHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3744721-B1 CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT SHIONOGI & CO (JP) 2025-07-02 — — EP disclosed
US-20240309038-A1 NOVEL GALACTOSIDE INHIBITOR OF GALECTINS GALECTO BIOTECH AB (DK) 2024-09-19 — — US disclosed
US-20240059728-A1 NOVEL GALACTOSIDE INHIBITOR OF GALECTINS GALECTO BIOTECH AB (DK) 2024-02-22 — — US disclosed
EP-4267568-A1 NOVEL GALACTOSIDE INHIBITOR OF GALECTINS Galecto Biotech AB (DK) 2023-11-01 — — EP disclosed
WO-2023118267-A1 NOVEL GALACTOSIDE INHIBITOR OF GALECTINS GALECTO BIOTECH AB (DK) 2023-06-29 — — WO disclosed
US-11578084-B2 Condensed ring compounds having dopamine D3 receptor antagonistic effect SHIONOGI & CO., LTD. (JP) 2023-02-14 — — US disclosed
WO-2022144274-A1 NOVEL GALACTOSIDE INHIBITOR OF GALECTINS GALECTO BIOTECH AB (DK) 2022-07-07 — — WO disclosed
EP-3368524-B1 HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2021-08-18 — — EP disclosed
US-20210040117-A1 CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT SHIONOGI & CO., LTD. (JP) 2021-02-11 — — US disclosed
EP-3744721-A1 CONDENSED CYCLIC COMPOUND HAVING DOPAMINE D3 RECEPTOR ANTAGONISM Shionogi & Co., Ltd (JP) 2020-12-02 — — EP disclosed
EP-1315739-B1 METHOD FOR BINDING, IN SOLUTION, A PEPTIDE AND A LIPOPHILIC VECTOR AND USES THEREOF PASTEUR INSTITUT (FR) 2004-08-18 — — EP disclosed
US-20040092015-A1 Method for binding, in solution, a peptide and a lipophilic vector and uses thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS (FR) 2004-05-13 — — US disclosed
US-20040024059-A1 Novel pleuromutilin derivatives SMITHKLINE BEECHAM P.L.C. (GB) 2004-02-05 — — US disclosed
EP-1206482-B1 METHOD FOR COUPLING, IN SOLUTION, A PEPTIDE WITH AT LEAST ANOTHER COMPOUND AND USES THEREOF PASTEUR INSTITUT (FR) 2003-09-24 — — EP disclosed
EP-1206482-A2 METHOD FOR COUPLING, IN SOLUTION, A PEPTIDE WITH AT LEAST ANOTHER COMPOUND AND USES THEREOF INSTITUT PASTEUR DE LILLE (FR) 2002-05-22 — — EP disclosed
WO-2001014408-A2 METHOD FOR COUPLING, IN SOLUTION, A PEPTIDE WITH AT LEAST ANOTHER COMPOUND AND USES THEREOF INSTITUT PASTEUR DE LILLE (FR) 2001-03-01 — — WO disclosed
EP-0853612-B1 ALPHA-HYDRAZINO ACID DERIVATIVES AND METHOD FOR MAKING SAME CENTRE NAT RECH SCIENT (FR) 2000-06-14 — — EP disclosed
US-5962722-A α-hydrazino acid derivatives and method for making same CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 1999-10-05 — — US disclosed
EP-0853612-A1 ALPHA-HYDRAZINO ACID DERIVATIVES AND METHOD FOR MAKING SAME CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 1998-07-22 — — EP disclosed
WO-1997009303-A1 ALPHA-HYDRAZINO ACID DERIVATIVES AND METHOD FOR MAKING SAME CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 1997-03-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024059-A1 Novel pleuromutilin derivatives PLEC, MLNR, FABP2 GPR119 925/4885AR 4877/4885HRH3 2207/4885
US-20240059728-A1 NOVEL GALACTOSIDE INHIBITOR OF GALECTINS LGALS1, LGALS3, LGALS2 GPR119 181/4885AR 3339/4885HRH3 4473/4885
US-20240309038-A1 NOVEL GALACTOSIDE INHIBITOR OF GALECTINS LGALS3, LGALS1, LGALS3BP GPR119 252/4885AR 1960/4885HRH3 3375/4885
US-20040092015-A1 Method for binding, in solution, a peptide and a lipophilic vector and uses thereof VIP, LIPE, LPXN GPR119 636/4885AR 1841/4885HRH3 927/4885
US-20210040117-A1 CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT DRD3, DRD2, DRD1 GPR119 120/4885AR 237/4885HRH3 62/4885
US-11578084-B2 Condensed ring compounds having dopamine D3 receptor antagonistic effect DRD3, DRD2, DRD1 GPR119 120/4885AR 237/4885HRH3 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.